We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-7.92%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$443M
AUM Growth
-$5.44M
Cap. Flow
-$82.1M
Cap. Flow %
-18.51%
Top 10 Hldgs %
47.3%
Holding
81
New
8
Increased
12
Reduced
20
Closed
11

Top Buys

Rank Stock Value
1
NVAX icon
Novavax
NVAX
+$11.8M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$8.15M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$6.61M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.34M
5
UTHR icon
United Therapeutics
UTHR
+$3.81M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$17.9M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$13.7M
3
GILD icon
Gilead Sciences
GILD
+$12.4M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$12.4M
5
BIIB icon
Biogen
BIIB
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.53%
2 Miscellaneous 0.47%
3 Utilities 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KOD icon
76
Kodiak Sciences
KOD
$2.46B
– –
-16,200
Closed -$1.37M
NKTR icon
77
Nektar Therapeutics
NKTR
$2.55B
– –
-4,467
Closed -$905K
STRO icon
78
Sutro Biopharma
STRO
$353M
– –
-13,933
Closed -$2.07M
ARNA
79
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-21,000
Closed -$1.95M
ZGNX
80
DELISTED
Zogenix, Inc.
ZGNX
– –
-135,000
Closed -$2.19M
1 2 3
4

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q1 2022 Portfolio in Review

As of Q1 2022, International Biotechnology Trust held 81 positions worth $443M, down 1.2% from $449M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

International Biotechnology Trust withdrew a net $82.1M in Q1 2022, closing 11 positions and reducing 20 holdings. Its most notable exit was Biogen, an estimated $11.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Miscellaneous and Utilities.

Against the trend, International Biotechnology Trust opened a new position in Novavax worth $18.5M.

  • International Biotechnology Trust's largest Q1 2022 buy was Novavax: 132,500 shares worth $18.5M.
  • International Biotechnology Trust added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2022, an estimated $8.15M increase.
  • International Biotechnology Trust's biggest Q1 2022 reduction was Amgen, cutting an estimated $17.9M.
  • International Biotechnology Trust fully exited Biogen in Q1 2022, selling an estimated $11.4M.
  • International Biotechnology Trust's ten largest holdings make up 47% of its $443M portfolio in Q1 2022.
  • International Biotechnology Trust opened 8 new positions and closed 11 in Q1 2022.
  • International Biotechnology Trust's portfolio value fell 1.2% quarter-over-quarter to $443M.

Based on International Biotechnology Trust's 13F filing for Q1 2022, filed 20 May 2022.